Nov 29, 2017 by Brian Orelli, PhDHere's How Alnylam Pharmaceuticals, Inc. Crushed It in 2017Positive phase 3 data for its lead drug, patisiran, helped shares more than triple this year.
Nov 27, 2017 by Brian Orelli, PhDBiogen Inc. Buys Its Way Out of CompetitionThe big biotech gains rights to a potential Tecfidera competitor from Alkermes.
Nov 21, 2017 by Brian Orelli, PhDWhy OraSure Technologies, Inc. Zoomed Higher TodayA large sale to a single customer has investors excited about the diagnostic company's prospects.
Nov 16, 2017 by Brian Orelli, PhDWhy Diplomat Pharmacy Inc Fell TodayInvestors aren't happy about the specialty pharmacy getting into the pharmacy benefit manager business.
Nov 16, 2017 by Brian Orelli, PhDGenomic Health, Inc. Turns a Profit (With an Asterisk)The company was only in the black on a non-GAAP basis.
Nov 15, 2017 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval NextAfter positive phase 3 data, the biotech's first drug is ready to be submitted to regulators.
Nov 14, 2017 by Brian Orelli, PhDIonis Pharmaceuticals Inc. Sets Itself Up for GrowthSpinraza sales continue to rise and the biotech has two drugs under review by regulators.
Nov 13, 2017 by Brian Orelli, PhDDiplomat Pharmacy Inc. Expands Its OfferingsThe specialty pharmacy is getting into the pharmacy benefit manager business.
Nov 13, 2017 by Brian Orelli, PhDQiagen NV Meets Its Own 3rd-Quarter ExpectationsBut investors would have liked to have seen more.
Nov 13, 2017 by Brian Orelli, PhDA Rare Quarterly Appearance by bluebird bio Inc.'s ManagementThe bigwigs came out to tout data to be presented at ASH.
Nov 10, 2017 by Brian Orelli, PhDMomenta Pharmaceuticals, Inc.'s Rough MonthThird-quarter earnings highlight bad news from the drugmaker.
Nov 10, 2017 by Brian Orelli, PhDWhy Immunomedics, Inc. Jumped Higher TodayA new CEO has the biotech's investors excited.
Nov 9, 2017 by Brian Orelli, PhDImmunoGen, Inc. Moves ForwardWith lead program Forward I not scheduled to read out until 2019, investors have to be content with data from an earlier stage.
Nov 9, 2017 by Brian Orelli, PhDWhy Idera Pharmaceuticals Inc. Jumped Higher TodayNew phase 1/2 trial data show the biotech's drug candidate IMO-2125 is working.
Nov 8, 2017 by Brian Orelli, PhDNew Contracts and Products Help Emergent BioSolutions Inc Get It DoneThe bioterrorism specialist posts a solid third quarter as it moves towards $1 billion in revenue in 2020.
Nov 8, 2017 by Brian Orelli, PhDBecton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of HeadwindsThe medical and life sciences conglomerate grows through cost savings.
Nov 7, 2017 by Brian Orelli, PhDWhy Diplomat Pharmacy Inc Fell TodayInvestors react to the huge run-up in price and the latest earnings report.
Nov 7, 2017 by Brian Orelli, PhDNovo Nordisk A/S Slogs Through the YearIt was another lackluster quarter from the diabetes specialist.
Nov 7, 2017 by Brian Orelli, PhDWhy Celldex Therapeutics Jumped Higher TodayData in the biotech's earnings release has investors optimistic.
Nov 6, 2017 by Brian Orelli, PhDExelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too ShabbyPotential label expansions are more important to the biotech's future than third-quarter sales of Cabometyx, but they still looked good.
